ClinicalTrials.gg
CompletedNCT03249376Updated Jun 3, 2022Results posted

Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

A Phase 3 interventional study of Lumateperone and Placebo in Bipolar Depression, sponsored by Intra-Cellular Therapies, Inc.. Completed at 47 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-03.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
381
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies in Bipolar Disorder by Johnson & Johnson — 2 open to participants now, 2 under way, 2 of them phase 3. Bipolar Disorder · Johnson & Johnson.

Enrollment
12th of 36
381 · median 300
Started
2017
the only one that year
Phase 3
28 of 39
2 open now
Registered
33rd of 39
by date

Among the 39 studies in Bipolar Disorder by Johnson & Johnson, this one is the 12th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2017, is one of 28 in phase 3, and was the 33rd registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 39 studies in Bipolar Disorder by Johnson & Johnson are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Bipolar Disorder by Johnson & Johnson, or all of them as a file.
02

Study summary

The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.

03

Conditions studied

  • Bipolar Depression

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • male or female subjects of any race, ages 18-75 inclusive, with a clinical diagnosis of Bipolar I or Bipolar II disorder
  • experiencing a current major depressive episode
  • able to provide written

Major Exclusion Criteria:

  • any female subject who is pregnant or breast-feeding
  • any subject judged to be medically inappropriate for study participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
381 participants (actual)

Study arms

  • Experimental
    Lumateperone

    Lumateperone 42 mg (ITI-007 60 mg tosylate) administered once daily every evening for 6 weeks

    Drug: Lumateperone

  • Placebo comparator
    Placebo

    Placebo administered once daily every evening for 6 weeks

    Other: Placebo

Interventions

  • Lumateperone 42 mg (ITI-007 60 mg tosylate)

    Also known as: ITI-007

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

    Time frame: Baseline to Day 43

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression Scale, Bipolar Version (CGI-BP-S) Total Score

    The Clinical Global Impression Scale, Bipolar version (CGI-BP-S) total score is a clinician-rated scale that measures the patient's current illness state on a 3 to 21 point scale where a higher score is associated with greater illness severity.. Each domain (depression, mania, and overall illness) is rated from 1 (not ill at all) to 7 (among the most extremely ill) and the 3 scores are added to obtain the total score.

    Time frame: Baseline to Day 43

  2. Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Percent Score

    The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) is a 14 item patient self-reported questionnaire that assesses how satisfied a patient is, using a 5-point scale from 1-very poor to 5-very good.

    Time frame: Baseline to Day 43

07

Results

Posted Jun 3, 2022

Participant flow

Participant flow — Overall Study
MilestoneLumateperonePlacebo
Started188189
Completed167166
Not completed2123
Withdrew: Adverse event115
Withdrew: Lack of efficacy24
Withdrew: Protocol violation32
Withdrew: Physician decision02
Withdrew: Withdrawal by subject39
Withdrew: Ltfu21

Outcome measures

PrimaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

Time frame:
Baseline to Day 43
Reported as:
Least squares mean · score on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
score on a scaleLumateperonePlacebo
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-16.70 ± 0.693-12.12 ± 0.677
Statistical analysis
  • Lumateperone vs Placebo · Mixed Effects Model for Repeated Measure · p = <0.0001 · Least squares mean difference: -4.6 · 95% CI -6.34 to -2.83
SecondaryChange From Baseline in Clinical Global Impression Scale, Bipolar Version (CGI-BP-S) Total Score

The Clinical Global Impression Scale, Bipolar version (CGI-BP-S) total score is a clinician-rated scale that measures the patient's current illness state on a 3 to 21 point scale where a higher score is associated with greater illness severity.. Each domain (depression, mania, and overall illness) is rated from 1 (not ill at all) to 7 (among the most extremely ill) and the 3 scores are added to obtain the total score.

Time frame:
Baseline to Day 43
Reported as:
Least squares mean · score on a scale
Change From Baseline in Clinical Global Impression Scale, Bipolar Version (CGI-BP-S) Total Score
score on a scaleLumateperonePlacebo
Change From Baseline in Clinical Global Impression Scale, Bipolar Version (CGI-BP-S) Total Score-3.48 ± 0.170-2.54 ± 0.167
Statistical analysis
  • Lumateperone vs Placebo · Mixed Effects Model for Repeated Measure · p = <0.0001 · Least squares mean difference: -0.9 · 95% CI -1.37 to -0.51
SecondaryChange From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Percent Score

The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) is a 14 item patient self-reported questionnaire that assesses how satisfied a patient is, using a 5-point scale from 1-very poor to 5-very good.

Time frame:
Baseline to Day 43
Reported as:
Least squares mean · Percent Score
Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Percent Score
Percent ScoreLumateperonePlacebo
Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Percent Score19.4 ± 1.4914.9 ± 1.45
Statistical analysis
  • Lumateperone vs Placebo · ANCOVA · p = 0.005 · Least squares mean difference: 4.6 · 95% CI 1.42 to 7.69

Adverse events

Collected over From signing ICF until end of study procedures (~10 weeks), including 6 weeks of double-blind treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lumateperone0/188 (0%)1/188 (0.5%)58/188 (30.9%)
Placebo0/189 (0%)0/189 (0%)31/189 (16.4%)
Most frequent serious events
Most frequent serious events
EventLumateperonePlacebo
ManiaPsychiatric disorders1/1880/189
Most frequent other events
Most frequent other events
EventLumateperonePlacebo
HeadacheNervous system disorders33/18819/189
SomnolenceNervous system disorders16/1882/189
NauseauGastrointestinal disorders12/1884/189
DizzinessNervous system disorders9/18810/189

Baseline characteristics

Age, Continuous
Age, Continuous(years)LumateperonePlaceboTotal
Mean45.7 ± 14.0944.1 ± 12.8744.9 ± 13.50
Sex: Female, Male
Sex: Female, Male(Participants)LumateperonePlaceboTotal
Female99120219
Male8969158
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LumateperonePlaceboTotal
Caucasian/White173171344
Black or African American141529
Asian101
Other033
Region of Enrollment
Region of Enrollment(participants)LumateperonePlaceboTotal
United States5159110
Ukraine493887
Bulgaria494392
Serbia61319
Russia323466
Colombia123
Montgomery-Asberg Depression Rating Scale (MADRS)
Montgomery-Asberg Depression Rating Scale (MADRS)(units on a scale)LumateperonePlaceboTotal
Mean30.8 ± 4.9230.2 ± 4.6530.5 ± 4.79
08

Study locations

47 sites
  • Clinical Site
    Birmingham, Alabama 35294, United States
  • Clinical Site
    Sherman Oaks, California 91403, United States
  • Clinical Site
    Miami, Florida 33133, United States
  • Clinical Site
    Orange City, Florida 32763, United States
  • Clinical Site
    Atlanta, Georgia 30322, United States
  • Clinical Site
    Decatur, Georgia 30030, United States
  • Clinical Site
    Chicago, Illinois 60612, United States
  • Clinical Site
    Joliet, Illinois 60435, United States
  • Clinical Site
    Shreveport, Louisiana 71101, United States
  • Clinical Site
    Saint Louis, Missouri 63128, United States
  • Clinical Site
    Buffalo, New York 14215, United States
  • Clinical Site
    Charlotte, North Carolina 28211, United States
  • Clinical Site
    The Woodlands, Texas 77381, United States
  • Clinical Site
    Bothell, Washington 98011, United States
  • Clinical Site
    Burgas, Bulgaria
  • Clinical Site
    Kardzhali, Bulgaria
  • Clinical Site
    Lovech, Bulgaria
  • Clinical Site
    Plovdiv, Bulgaria
  • Clinical Site
    Ruse, Bulgaria
  • Clinical Site
    Sofia, Bulgaria
  • Clinical Site
    Targovishte, Bulgaria
  • Clinical Site
    Tsarev Brod, Bulgaria
  • Clinical Site
    Varna, Bulgaria
  • Clinical Site
    Veliko Tarnovo, Bulgaria
  • Clinical Site
    Barranquilla, Colombia
  • Clinical Site
    Bello, Colombia
  • Clinical Site
    Pereira, Colombia
  • Clinical Site
    Ekaterinburg, Russian Federation
  • Clinical Site
    Moscow, Russian Federation
  • Clinical Site
    Nizhny Novgorod, Russian Federation
  • Clinical Site
    Omsk, Russian Federation
  • Clinical Site
    Saint Petersburg, Russian Federation
  • Clinical Site
    Samara, Russian Federation
  • Clinical Site
    Saratov, Russian Federation
  • Clinical Site
    Tomsk, Russian Federation
  • Clinical Site
    Belgrade, Serbia
  • Clinical Site
    Kragujevac, Serbia
  • Clinical Site
    Novi Sad, Serbia
  • Clinical Site
    Ivano-Frankivs'k, Ukraine
  • Clinical Site
    Kharkiv, Ukraine
  • Clinical Site
    Kherson, Ukraine
  • Clinical Site
    Lviv, Ukraine
  • Clinical Site
    Odesa, Ukraine
  • Clinical Site
    Poltava, Ukraine
  • Clinical Site
    Smila, Ukraine
  • Clinical Site
    Uzhgorod, Ukraine
  • Clinical Site
    Vinnytsia, Ukraine
09

References and documents

Publications

  • Calabrese JR, Durgam S, Satlin A, Vanover KE, Davis RE, Chen R, Kozauer SG, Mates S, Sachs GS. Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial. Am J Psychiatry. 2021 Dec;178(12):1098-1106. doi: 10.1176/appi.ajp.2021.20091339. Epub 2021 Sep 23. PubMed 34551584 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Mar 2019, 15 months.

Results were first posted in Jun 2022, 3 years 3 months after primary completion. A results delay was requested in Apr 2020.

Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 15 months is below that.

Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2017
First posted
Aug 15, 2017
StartActual
Nov 27, 2017
Primary completionActual
Mar 1, 2019
CompletionActual
Mar 1, 2019
Results delay requested
Apr 9, 2020
Results first posted
Jun 3, 2022
Last update
Jun 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03249376
Responsible party
Sponsor
First posted
Aug 15, 2017
Start date
Nov 27, 2017
Primary completion
Mar 1, 2019
Completion
Mar 1, 2019
Results posted
Jun 3, 2022
Last update
Jun 3, 2022

Study contacts

Susan Kozauer, MD
study director · Intra-Cellular Therapies, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion